4 Healthcare Stock Stories For Midweek Investment Wellness

| + More Articles
  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

GlaxoSmithKline (NYSE:GSK): Closing price $50.60

The firm recently reached an agreement with Renaissance Acquisition Holdings, granting it rights in the United States to make and commercialize nine Glaxo products that will be marketed by Prestium Pharma, a subsidiary of Renaissance. Financial details of the deal were not divulged. Products covered under the terms include six dermatology products: Evoclin foam, Extina foam, Luxiq foam, Olux foam, Olux-E foam, and Vusion ointment. Three anti-viral products are Zovirax capsules, Zovirax tablets, and Zovirax suspension.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

GSK

More Articles About:

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business